EP
FATE icon

Essential Partners’s Fate Therapeutics FATE Stock Holding History

Essential Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.02K Sell
2,231
-8,987
-80% -$16.6K ﹤0.01% 1459
2026
Q1 		$13.5K Buy
11,218
+10,404
+1,278% +$12.7K ﹤0.01% 1099
2025
Q4 		$800 Sell
814
-416
-34% -$500 ﹤0.01% 2099
2025
Q3 		$1.55K Buy
1,230
+608
+98% +$656 ﹤0.01% 1876
2025
Q2 		$697 Buy
+622
New +$723 ﹤0.01% 1604

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Essential Partners's FATE Position: Q2 2026 in Review

Essential Partners reduced its Fate Therapeutics (FATE) stake by 80% in Q2 2026, selling an estimated $16.6K and leaving 2,231 shares worth $6.02K. The position accounts for ﹤0.01% of the portfolio, ranked #1459.

Essential Partners first reported a position in FATE in Q2 2025 and has held it in 5 quarters since. The position peaked at $13.5K in Q1 2026. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Essential Partners held 2,231 shares of Fate Therapeutics worth $6.02K as of Q2 2026.
  • Essential Partners sold 8,987 Fate Therapeutics shares in Q2 2026, an estimated $16.6K.
  • Fate Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1459 holding.
  • Essential Partners first reported a position in Fate Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Fate Therapeutics position peaked at $13.5K in Q1 2026.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.